Tuesday, July 21, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $324.56 -0.62%
MSFT $401.42 -0.22%
GOOGL $348.76 -0.92%
AMZN $248.20 -0.72%
TSLA $376.13 +1.78%
META $644.53 -0.20%
NVDA $207.25 +1.95%
JPM $339.08 +0.06%
BTC $29.41 +2.12%
ETH $18.44 +1.93%
AAPL
$324.56
▼ 0.62%
MSFT
$401.42
▼ 0.22%
GOOGL
$348.76
▼ 0.92%
AMZN
$248.20
▼ 0.72%
TSLA
$376.13
▲ 1.78%
META
$644.53
▼ 0.20%
NVDA
$207.25
▲ 1.95%
JPM
$339.08
▲ 0.06%
All Markets Technology Economy Science Health Sports Entertainment Politics
Bloomberg Markets
How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150-year history, concedes that one was a pu
business  Jun 23, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free